"We are committed to managing our estate in a sustainable manner in line with the UK Government Sustainable Development Strategy. As part of this, we will address social, economic and environmental issues when taking decisions and aim to reduce, the impact that our operations have on the environment. We have achieved ISO 14001 status for our environmental management system".This is very impressive, says Merpel, but there must be other ways to save energy and preserving the environment. How about recycling old inventions, instead of expecting patent applicants to provide new ones each time?
JIPLP's December 2010 editorial, which you can read online here. It deals with the shattered expectations of many small-scale would-be licensees of merchantable characters. The November issue of Intellectual Property Magazine carries a special focus on media and sport, but the IPKat's recommendation in this issue is "Losartan: a modern parable of pharma patent lifecycle management" by Innovate Legal's Duncan Curley and Amanda Easey. The September-October issue of World Intellectual Property Review carries interviews with MARQUES Chairman Guido Baumgartner and new European Patent Office head Benoît Battistelli, plus a fascinating piece by Arnold & Siedsma's Michiel Rijsdijk, "The Exceptio Plurium Litis Consortium", which deserves a longer treatment for the benefit of common lawyers and non-Latin speakers.
here. More IP litigation wisdom comes from The Bright Spark in "Tactics -- the benefits of just giving up", on the advantages that can be gleaned from submitting to an adverse judgment at an early stage. Writing in IP Finance, fellow Kat Neil Wilkof ("Meet the Trademark Troll") has provoked some pungent comment. If you agree with him -- or not -- feel free to join the debate. Finally, Filemot ("The End of Patent Agents", here) has been indulging in a little debating of her own, on SOLO IP.
|The Yeti: only a little less frequently|
referred to in patent litigation than
the Community Patent Convention
"The Dutch decision is in line with German case law. The Bundesgerichtshof in its decision of 5 December 2006 (Simvastatin) ruled that publication in the so-called Lauer-taxe (the German equivalent of the Dutch G-standaard) constitutes infringement, even if it is indicated that delivery will only take place after the expiration of the patent.
The High Court of England & Wales seems to hold a different view. In Gerber v Lectra ( RPC 383 at 411), a case that did not relate to ‘offering for sale’ in a database for medicaments as the German and Dutch decisions do, the High Court (Jacob J) ruled that offering a patented product for sale within the term of the patent for supply after the expiry of the patent, does not constitute an infringing act".
|Networking at an IPSoc social ...|
here, we'll all be very happy.
|UEA is known for its unusual|
candidate selection process
"The year is 1917, and all over England, scientists engaged in top secret research for the war effort are disappearing, quite literally in a puff of smoke. In each case, the disappearance can be linked to receipt of a copy of an obscure and apparently innocuous German patent, No 12,096 of 1880, for the preparation of red, violet, and green dyestuffs by the action of chloropicrin on aromatic amines.
But this was no ordinary patent. No less a figure than the Government's leading expert on chemical warfare, Professor William Pope FRS has declared: ‘anyone who attempted to repeat the method [of the ’096 patent] would be pretty certain to kill himself during the operation'.
Will the country's favourite consulting detective (and amateur chemist) solve the mystery of the deadly dyestuff disappearances, or is Sherlock Holmes himself destined for extinction, as the latest victim of the mysterious and malevolent ‘Picric Club’?" (non-subscribers can still read this wonderful piece on a pay-per-view basis by clicking here and scrolling down ...)